The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Guizhou Xinbang Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.02% CNY3.96
America/New_York / 30 apr 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7 184.31 mill |
| EPS: | 0.120 |
| P/E: | 33.00 |
| Earnings Date: | Apr 16, 2024 |
| SharesOutstanding: | 1 814.22 mill |
| Avg Daily Volume: | 19.03 mill |
| RATING 2024-04-30 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.92x |
| Company: PE 33.00 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.72x |
| Company: PE 33.00 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY3.71 (-6.19%) CNY-0.245 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 3.86 - 4.06 ( +/- 2.42%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY3.96 (1.02% ) |
| Volume | 22.73 mill |
| Avg. Vol. | 19.03 mill |
| % of Avg. Vol | 119.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 002390.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
002390.SZ
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.